Verona Pharma Plc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2025 to a ratio of 4.83, this represents a new company high. This is a clear indication for improving liquidity at Verona Pharma Plc's clients. Average receivable collection period, for the Verona Pharma Plc in Jun 30 2025 quarter, has decreased to 76 days, compared to 77 days, in the Mar 31 2025 quarter.

If we take a look into Healthcare sector 386 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2025 from 0 to 2764.

What is Receivable Turnover Ratio?
What is Verona Pharma Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VRNA Receivables Turnover Ratio	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Receivable Change	-	-	-	-	-
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	4.83	4.72	4.4	3.26	-
VRNA's Total Ranking	# 2764	# 0	# 0	# 0	# 0
Accounts Receivable average collection period days	76	77	83	112	-
Seq. Receivable Change	33.3 %	97.36 %	356.2 %	-	-
Seq. Revenue Change	35.25 %	108.04 %	551.76 %	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 115
Healthcare Sector	# 387
Overall Market	# 2764

Receivable Turnover Ratio Statistics
High	Average	Low
4.83	4.83	4.83
(Jun 30 2025)

VRNA Company Profile • Back to VRNA Efficiency Comparisons • Compare VRNA Receivables Turnover Ratio to its Competitors

Financial Statements
Verona Pharma Plc's Accounts Receivable	$ 83 Millions	Visit VRNA's Balance sheet
Verona Pharma Plc's Sales TTM	$ 222 Millions	Visit VRNA's Income Statement
Sources of VRNA's Revenues		Visit VRNA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VRNA's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VRNA's Growth Rates	VRNA's Roa	VRNA's Inventory Turnover Ratio	VRNA's Dividend Comparisons
VRNA's Profitability Ratios	VRNA's Roi	VRNA's Asset Turnover Ratio	VRNA's Dividend Growth
VRNA's Valuation Ratios	VRNA's Roe	VRNA's Financial Strength Ratios	VRNA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2025	Receivable at quarter ending Jun 30 2025
Becton Dickinson And Company	7.35	$ 21,386.000 Millions	$ 2,910.750 Millions
Dbv Technologies S a	7.29	$ 3.848 Millions	$ 0.528 Millions
Pacs Group Inc	7.26	$ 4,820.579 Millions	$ 663.877 Millions
Universal Health Services Inc	7.23	$ 16,460.285 Millions	$ 2,276.448 Millions
Kyntra Bio Inc	7.19	$ 53.555 Millions	$ 7.449 Millions
Cue Biopharma Inc	7.16	$ 8.287 Millions	$ 1.157 Millions
Si bone inc	7.12	$ 184.182 Millions	$ 25.861 Millions
3m Company	7.04	$ 24,602.000 Millions	$ 3,495.750 Millions
Sight Sciences Inc	7.03	$ 75.149 Millions	$ 10.688 Millions
Ardelyx inc	7.02	$ 386.146 Millions	$ 54.980 Millions
Avita Medical Inc	7.02	$ 74.884 Millions	$ 10.671 Millions
Boston Scientific Corporation	7.00	$ 18,494.000 Millions	$ 2,641.750 Millions
Lemaitre Vascular Inc	6.99	$ 234.162 Millions	$ 33.495 Millions
Adm Tronics Unlimited Inc	6.99	$ 3.313 Millions	$ 0.474 Millions
Maravai Lifesciences Holdings Inc	6.98	$ 215.853 Millions	$ 30.942 Millions
Rigel Pharmaceuticals Inc	6.98	$ 267.921 Millions	$ 38.411 Millions
Iradimed Corporation	6.97	$ 77.635 Millions	$ 11.137 Millions
Maxcyte inc	6.97	$ 35.753 Millions	$ 5.130 Millions
Medpace Holdings Inc	6.95	$ 2,231.787 Millions	$ 321.012 Millions
Puma Biotechnology Inc	6.91	$ 238.062 Millions	$ 34.434 Millions
Vaso Corporation	6.89	$ 87.297 Millions	$ 12.672 Millions
Hca Healthcare Inc	6.89	$ 72,698.000 Millions	$ 10,553.250 Millions
Phibro Animal Health Corporation	6.86	$ 1,295.942 Millions	$ 188.933 Millions
Ceribell Inc	6.86	$ 76.234 Millions	$ 11.115 Millions
Angiodynamics Inc	6.86	$ 290.645 Millions	$ 42.383 Millions
Legend Biotech Corporation	6.85	$ 255.058 Millions	$ 37.257 Millions
Tela Bio Inc	6.84	$ 73.696 Millions	$ 10.778 Millions
Cerus Corporation	6.83	$ 190.983 Millions	$ 27.969 Millions
Nexalin Technology Inc	6.82	$ 0.175 Millions	$ 0.026 Millions
Solventum Corporation	6.82	$ 8,388.000 Millions	$ 1,230.500 Millions

Date modified: 2026-07-07T14:08:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.